Weisberg EL - Search Results

1

Structure-guided development of covalent TAK1 inhibitors.

Tan L, Gurbani D, Weisberg EL, Hunter JC, Li L, Jones DS, Ficarro SB, Mowafy S, Tam CP, Rao S, Du G, Griffin JD, Sorger PK, Marto JA, Westover KD, Gray NS. Tan L, et al. Among authors: weisberg el. Bioorg Med Chem. 2017 Feb 1;25(3):838-846. doi: 10.1016/j.bmc.2016.11.035. Epub 2016 Dec 9. Bioorg Med Chem. 2017. PMID: 28011204 Free PMC article.

2

Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.

Weisberg E, Griffin JD. Weisberg E, et al. Blood. 2000 Jun 1;95(11):3498-505. Blood. 2000. PMID: 10828035 Free article.

3

ARG tyrosine kinase activity is inhibited by STI571.

Okuda K, Weisberg E, Gilliland DG, Griffin JD. Okuda K, et al. Blood. 2001 Apr 15;97(8):2440-8. doi: 10.1182/blood.v97.8.2440. Blood. 2001. PMID: 11290609 Free article.

4

Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients.

Weisberg E, Griffin JD. Weisberg E, et al. Drug Resist Updat. 2001 Feb;4(1):22-8. doi: 10.1054/drup.2001.0180. Drug Resist Updat. 2001. PMID: 11512149 Review.

5

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, Gilliland DG, Griffin JD. Weisberg E, et al. Cancer Cell. 2002 Jun;1(5):433-43. doi: 10.1016/s1535-6108(02)00069-7. Cancer Cell. 2002. PMID: 12124173 Free article.

6

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.

Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, Griffin JD, Wood J, Munshi NC, Anderson KC. Lin B, et al. Cancer Res. 2002 Sep 1;62(17):5019-26. Cancer Res. 2002. PMID: 12208756

7

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, Curley DP, Duclos N, Rowan R, Kutok JL, Lee BH, Williams IR, Coutre SE, Stone RM, DeAngelo DJ, Marynen P, Manley PW, Meyer T, Fabbro D, Neuberg D, Weisberg E, Griffin JD, Gilliland DG. Cools J, et al. Cancer Cell. 2003 May;3(5):459-69. doi: 10.1016/s1535-6108(03)00108-9. Cancer Cell. 2003. PMID: 12781364 Free article.

8

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.

Sattler M, Scheijen B, Weisberg E, Griffin JD. Sattler M, et al. Adv Exp Med Biol. 2003;532:121-40. doi: 10.1007/978-1-4615-0081-0_11. Adv Exp Med Biol. 2003. PMID: 12908554 Review.

9

Resistance to imatinib (Glivec): update on clinical mechanisms.

Weisberg E, Griffin JD. Weisberg E, et al. Drug Resist Updat. 2003 Oct;6(5):231-8. doi: 10.1016/s1368-7646(03)00062-1. Drug Resist Updat. 2003. PMID: 14643293 Review.

10

Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways.

Sawafuji K, Miyakawa Y, Weisberg E, Griffin JD, Ikeda Y, Kizaki M. Sawafuji K, et al. Leuk Lymphoma. 2003 Nov;44(11):1987-96. doi: 10.1080/1042819031000122033. Leuk Lymphoma. 2003. PMID: 14738154

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

119 results

Search Page

Filters